372 related articles for article (PubMed ID: 2436387)
1. [The interferon system. A review of biological principles and clinical uses].
Schneider FJ
Z Gesamte Inn Med; 1986 Nov; 41(22):613-8. PubMed ID: 2436387
[TBL] [Abstract][Full Text] [Related]
2. [Interferons--biologic principles and clinical uses].
Jacobsen H; Kirchner H
Klin Padiatr; 1985; 197(4):263-7. PubMed ID: 3930830
[TBL] [Abstract][Full Text] [Related]
3. [Interferons: physiology, pharmacology and pharmacotherapeutic perspectives].
Billiau A
J Pharmacol; 1983; 14 Suppl 3():105-16. PubMed ID: 6200731
[TBL] [Abstract][Full Text] [Related]
4. [Current status of interferon therapy].
Dittrich C
Wien Med Wochenschr; 1986 Apr; 136(7-8):163-72. PubMed ID: 2425497
[TBL] [Abstract][Full Text] [Related]
5. [Interferon--properties and action].
Zamorska I; Kozłowski M
Wiad Lek; 1989 Oct 1-Nov 1; 42(19-21):1086-91. PubMed ID: 2517808
[TBL] [Abstract][Full Text] [Related]
6. Independent evolution of antiviral and growth-modulating activities of interferon.
Carter WA; Swartz H; Gillespie DH
J Biol Response Mod; 1985 Oct; 4(5):447-59. PubMed ID: 2416881
[TBL] [Abstract][Full Text] [Related]
7. [Possibilities and limits of the use of interferons in the clinic].
Ludwig CU
Schweiz Med Wochenschr; 1989 Nov; 119(44):1539-43. PubMed ID: 2479977
[TBL] [Abstract][Full Text] [Related]
8. Interferon-induced alterations in cells: relevance to viral and nonviral diseases.
Preble OT; Friedman RM
Lab Invest; 1983 Jul; 49(1):4-18. PubMed ID: 6191121
[TBL] [Abstract][Full Text] [Related]
9. Effect of hyperthermia on the antiproliferative activities of murine alpha-, beta-, and gamma-interferon: differential enhancement of murine gamma-interferon.
Fleischmann WR; Fleischmann CM; Gindhart TD
Cancer Res; 1986 Jan; 46(1):8-13. PubMed ID: 2998611
[TBL] [Abstract][Full Text] [Related]
10. In vivo myelosuppression by combination interferon treatment: antagonism of MuIFN-gamma and MuIFN-beta myelosuppressive effects.
Naldini A; Fleischmann WR
J Biol Response Mod; 1987 Oct; 6(5):546-55. PubMed ID: 3119781
[TBL] [Abstract][Full Text] [Related]
11. The interferons.
Itri LM
Cancer; 1992 Aug; 70(4 Suppl):940-5. PubMed ID: 1379116
[TBL] [Abstract][Full Text] [Related]
12. [The interferon system with special reference to gamma-interferons].
Kirchner H
Dtsch Med Wochenschr; 1986 Jan; 111(2):64-70. PubMed ID: 2416525
[No Abstract] [Full Text] [Related]
13. [Experimental research to clinical application of interferons].
Imamishi J; Tanaka A
Gan To Kagaku Ryoho; 1984 Jan; 11(1):53-9. PubMed ID: 6198966
[TBL] [Abstract][Full Text] [Related]
14. Current view on the perspectives of interferon therapy.
Borecký L
Acta Virol; 1986 Mar; 30(2):161-9. PubMed ID: 2425613
[TBL] [Abstract][Full Text] [Related]
15. Regulation of class II MHC gene expression by interferons: insights into the mechanism of action of interferon (review).
Giacomini P; Fisher PB; Duigou GJ; Gambari R; Natali PG
Anticancer Res; 1988; 8(6):1153-61. PubMed ID: 2464333
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the human interferon system in viral disease.
Levin S; Hahn T
Clin Exp Immunol; 1981 Dec; 46(3):475-83. PubMed ID: 6175461
[TBL] [Abstract][Full Text] [Related]
17. [Interferon--a new therapeutic principle].
Micksche M
Wien Med Wochenschr; 1993; 143(16-17):408-12. PubMed ID: 8273362
[TBL] [Abstract][Full Text] [Related]
18. [Update on the use of interferons in clinical practice].
Lauta VM
Clin Ter; 1995; 146(6-7):393-448. PubMed ID: 7586995
[TBL] [Abstract][Full Text] [Related]
19. Characterization of antiviral activity of spotted souslik (Spermophilus suslicus) interferons.
Kandefer-Szerszeń M
Arch Immunol Ther Exp (Warsz); 1987; 35(4):489-99. PubMed ID: 2449874
[TBL] [Abstract][Full Text] [Related]
20. [Human interferons -- features and chances (author's transl)].
Pohl A; Moser K; Micksche M
Wien Klin Wochenschr; 1981 Jul; 93(14):439-57. PubMed ID: 6168122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
